• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Asthma - Pipeline Review, Q4 2010 - Product Image

Asthma - Pipeline Review, Q4 2010

  • ID: 1464179
  • December 2010
  • 186 pages
  • Global Markets Direct

Asthma - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Asthma Pipeline Review, Q4 2010”, provides an overview of the Asthma therapeutic pipeline. This report provides information on the therapeutic development for Asthma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Asthma. “Asthma-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Asthma.
- A review of the Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Asthma Overview
Therapeutics Development
An Overview of Pipeline Products for Asthma
Asthma Therapeutics under Development by Companies
Asthma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Asthma Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Boehringer Ingelheim GmbH
Kyowa Hakko Kirin Co., Ltd.
Clinical Data, Inc.
Abbott Laboratories
Shionogi & Co., Ltd.
EpiGenesis Pharmaceuticals, Inc.
Amgen Inc.
Sanofi-Aventis
AstraZeneca PLC
GlaxoSmithKline plc
Merck & Co., Inc.
Dainippon Sumitomo Pharma Co., Ltd.
Micromet, Inc.
Takeda Pharmaceutical Company Limited
SkyePharma PLC
Vectura Group plc
Pearl Therapeutics, Inc.
Acusphere, Inc.
Nycomed International Management GmbH
AKELA Pharma Inc.
Novagali Pharma SA
Novartis AG
Actelion Ltd
Cephalon, Inc.
Chiesi Farmaceutici SpA
Dong-A Pharmaceutical Co., Ltd.
Glenmark Pharmaceuticals Ltd.
Mitsubishi Tanabe Pharma Corporation
Pfizer Inc.
Rigel Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited
Paratek Pharmaceuticals, Inc.
PARI Pharma GmbH
Icagen Inc
Antisense Therapeutics Limited
Idera Pharmaceuticals, Inc.
Lotus Pharmaceuticals, Inc.
Almirall, S.A.
Lpath, Inc.
MediciNova, Inc.
Biota Holdings Limited
NicOx SA
Compugen Ltd.
Pacgen Biopharmaceuticals Corporation
Palatin Technologies, Inc.
Pharmaxis Ltd.
MAP Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc
Cytokinetics, Inc
Dynavax Technologies Corporation
Phytopharm Plc
Stallergenes S.A.
Hanall Pharmaceutical Co., Ltd.
Cytos Biotechnology AG
Ahn-Gook Pharmaceutical Co., Ltd.
Biotie Therapies Corp.
NitroMed, Inc.
Neurim Pharmaceuticals (1991) Ltd.
Synairgen plc
Synta Pharmaceuticals Corp.
Orexo AB
e-Therapeutics plc
InDex Pharmaceuticals AB
Amphastar Pharmaceuticals, Inc.
Verona Pharma Plc
Eisai Inc.
Affimed Therapeutics AG
Alba Therapeutics Corporation
Immupharma Plc
Palau Pharma S.A
7TM Pharma A/S
Pieris AG
Respiratorius AB
Hutchison MediPharma Limited
Cosmix Molecular Biologicals GmbH
Calistoga Pharmaceuticals, Inc.
REVOTAR Biopharmaceuticals AG
Arriva Pharmaceuticals, Inc.
Circassia Holdings Ltd.
Funxional Therapeutics Ltd
ZaBeCor Pharmaceuticals
Promedior, Inc.
Altair Therapeutics, Inc.
Oxagen Limited
Heat Biologics, Inc.
Pulmatrix, Inc.
Reata Pharmaceuticals, Inc.
Rottapharm SpA
Amira Pharmaceuticals, Inc.
Indus Biotech Private Limited
AIM Therapeutics Inc.
Hydra Biosciences, Inc.
CyDex Pharmaceuticals, Inc.
Theraclone Sciences, Inc.
Vantia Therapeutics
Biotica Technology Ltd
Inverseon, Inc.
Resistentia Pharmaceuticals AB
BaroFold, Inc.
Taligen Therapeutics Inc.
KaloBios Pharmaceuticals, Inc.
AB Science
Resolvyx Pharmaceuticals, Inc
KYORIN Pharmaceutical Co., Ltd.
Laboratorios LETI S.L.
Aerovance, Inc.
NexBio, Inc.
Medigreen Biotechnology Corporation
Endacea, Inc.
Kemin Industries, Inc.
MEDA Pharma GmbH & Co. KG
Asmacure Limited
Yoo Young Pharmaceutical Co., Ltd.
Cellceutix Pharmaceuticals, Inc.
N30 Pharmaceuticals
Eurofarma
Mankind Pharma Limited
Immune Technologies and Medicine
Asklepion Pharmaceuticals, LLC.
Universities/Institutes Involved in Asthma Therapeutics Development
Asthma Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Anti-inflammatory drug - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APTA-2217 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Azithromycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BDP + Salbutamol HFA pMDI - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bricanyl Turbuhaler - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR-2039 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Daxas - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ETX9101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Flutiform - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Flutiform - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Formoterol/Budesonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK685698 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KCA-757 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nasonex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Procaterol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pulmicort + Bricanyl - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Relovair - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Spiriva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Staloral - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VR315 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Azithromycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Azithromycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Beclomethasone + Theophylline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Beclomethasone dipropionate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Beclomethasone dipropionate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Beclomethasone dipropionate + Albuterol sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biaxin + Flovent - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Budesonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Budesonide + albuterol + Ipratropium bromide + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Budesonide + Formoterol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Budesonide + Montelukast - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ciclesonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clarithromycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Esomeprazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Flovent Diskus + Singulair - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluticasone propionate + Montelukast - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lansoprazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
montelukast - Drug Profile
Product Description
Mechanism of Action
R&D Progress
montelukast - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Montelukast - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Montelukast Sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Montelukast Sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-Nitro L-arginine-methylester - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nedocromil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Omalizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prednisolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
prednisone + colecalciferol + lactose - Drug Profile
Product Description
Mechanism of Action
R&D Progress
prednisone + lactose - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RhuMab-E25 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rosiglitazone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Salmeterol + Beclomethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Simvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Simvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Theophylline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tiotropium bromide + Salmeterol xinofoate + Beclomethasone dipropionate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Asthma - Featured News
Dec 07, 2010: Pharmaxis Initiates Phase II Trial Of ASM8 In Asthma Patients
Nov 26, 2010: Verona Pharma To Initiate New Higher Dose RPL554 Clinical Trial In Asthma
Nov 22, 2010: SkyePharma Announces Commencement Of Phase III Trials For Asthma Drug In Japan
Nov 11, 2010: NexBio Presents Data At ACAAI 2010 Demonstrating Mechanism Of Action For Improvement In Airway Function By DAS181
Oct 27, 2010: Lotus Receives Japanese Approval To Initiate Phase I Clinical Trials Of Asthma Drug R-Bambuterol
Sep 30, 2010: Circassia Initiates Phase II Trials Of Novel Grass And Ragweed Allergy Therapies And Advances Phase III Plans For Cat Allergy T-cell Vaccine
Sep 30, 2010: Circassia Initiates Phase II Trials Of Novel Grass And Ragweed Allergy Therapies And Advances Phase III Plans For Cat Allergy T-cell Vaccine
Sep 08, 2010: N30 Pharma Initiates Phase I Trial Of N6022
Sep 08, 2010: Teva Announces Publication Of Results From Real-World Study In Journal Of Allergy And Clinical Immunology
Aug 26, 2010: Lotus Enters R-Bambuterol Clinical Trial I
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos